Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function Suppression<br /> vs Tamoxifen plus Ovarian Function Suppression<br />in Premenopausal Women <br />with Hormone Receptor Positive Early Breast Cancer: <br />Joint Analysis of IBCSG TEXT and SOFT
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
TEXT and SOFT
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
TEXT and SOFT Worldwide Collaborative
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Premenopausal Endocrine Therapy
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
TEXT - SOFT Trials<br />Aromatase Inhibitor Question
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
TEXT and SOFT Designs
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Eligibility
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Treatments
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Study Procedures
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Endpoints
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Statistical Considerations
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Characteristics
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Exemestane+OFS Improved DFS
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Sites of First Failure
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Exemestane+OFS Reduced Recurrence
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Women Who Did Not Receive Chemotherapy
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Women Who Received Chemotherapy
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Selected Adverse Events
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Adverse Events and QOL
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Conclusions
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
More from TEXT and SOFT
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
Slide 22
Presented By Olivia Pagani at 2014 ASCO Annual Meeting
